Emerging Markets Debt Income Fund Outperforms in Q1
Finance

Emerging Markets Debt Income Fund Outperforms in Q1

authorBy Robert Kiyosaki
DateJun 10, 2026
Read time1 min

In the first quarter, the Virtus Stone Harbor Emerging Markets Debt Income Fund (Class I) demonstrated strong performance, achieving a return of -0.93%. This result notably surpassed its benchmark, the J.P. Morgan EMBI Global Diversified Index, which registered a return of -1.26% over the same period. This positive differential underscores the fund's effective management in a challenging market environment.

Key contributors to this outperformance were strategic allocations and selections within hard currency sovereign debt. Significant gains were observed from an overweight position in Venezuela and specific issuer selections in Ukraine and Panama. Conversely, underweight positions in Bahrain and the UAE also played a crucial role in enhancing the fund's returns. During this quarter, only two countries within the investment-grade segment managed to deliver positive returns, reflecting the broader market's difficult conditions.

The fund's success in navigating the complexities of the emerging markets debt landscape during Q1, particularly amidst rising U.S. rates and geopolitical tensions in the Middle East, suggests the value of active management. The ability to identify and capitalize on opportunities in specific sovereign debts, while judiciously avoiding underperforming areas, highlights a disciplined investment philosophy. This strategic approach is essential for investors seeking to generate alpha in diverse and often unpredictable global markets.

More Articles
Finance
Interparfums: A Fine Fragrance Machine, But 2026 Is A Bridge Year
Interparfums maintains its standing as a premier fragrance company, known for its diverse license portfolio, robust cash generation, and cautious financial practices. Despite its strong foundation, the company's 2026 outlook, featuring stable sales and reduced earnings per share, suggests a transitional period. This projection has led to a 'Hold' recommendation, as current shareholders may choose to retain their investment, but new investors are advised to await more favorable entry points or clearer growth prospects.
By Michele FerreroJun 10, 2026
Finance
Seagate Faces Valuation Concerns Amidst Strong Memory Chip Competition
Seagate (STX) is currently rated as a 'sell' due to its premium valuation compared to more profitable and rapidly expanding memory chip manufacturers like Micron (MU) and Sandisk (SNDK). Although STX benefits from increased volume and enhanced margins through HAMR technology, its pricing flexibility is limited, and its contribution to AI data centers is perceived as less valuable. Despite analyst projections for significant free cash flow and EPS growth, the company's growth trajectory is expected to decelerate, leaving its valuation elevated. A potential downside of 19% is anticipated, with a 12-month price target of $710, primarily due to risks associated with AI data center development and market cyclicality.
By David RubensteinJun 10, 2026
Finance
The Cloud Economy: From Weightless Assets to Tangible Infrastructure
This article explores the evolution of the cloud economy, shifting from a focus on intangible assets like subscriptions and user engagement to the crucial role of tangible infrastructure and the concept of 'tokens' as a key metric. It highlights the growing complexity of the ecosystem, the rapid adoption of large language models (LLMs), and the enduring value found in AI infrastructure compared to software or hyperscalers.
By David RubensteinJun 10, 2026
Finance
Avalo Therapeutics: Navigating the Rollercoaster of Abdakibart's Clinical Journey
Avalo Therapeutics' stock experienced a full cycle after the positive Phase 2 results for abdakibart, its key clinical asset for hidradenitis suppurativa. Despite promising efficacy, the company faces a long development path. A recent $405 million secondary offering secured funding through the pivotal Phase 3 readout but significantly diluted shareholders by 65%. Abdakibart's performance against existing treatments and competitors, along with the high placebo response in trials, will be crucial as it advances.
By Nouriel RoubiniJun 10, 2026
Finance
PepsiCo: A Strong Buy with Significant Upside Potential
PepsiCo is currently rated as a strong buy, presenting an attractive investment opportunity with a projected 30% upside and a starting dividend yield of 4.2%. The company's recent financial results demonstrate accelerated organic growth and improved operating margins across all segments. Despite facing some short-term risks, PepsiCo's long-term fundamentals and commitment to dividend growth remain robust, making it a compelling choice for investors.
By David RubensteinJun 10, 2026